TriSalus Life Sciences, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Great. First of all, thank you so much to the Canaccord team. I'm delighted to be here. I think I'm going to move around. That light is right in my face. Good morning, everyone. I'm CEO of Trisalus Life Sciences. This is a company that is very science-driven, innovative, and we've developed a technology that actually improves therapeutic delivery into solid tumors. We do that through this very unique technology on the end of a catheter of a smart valve that modulates pressure and flow. We can improve the amount of therapeutic that's delivered into a solid tumor up for anywhere from 50% to 500%. Importantly, we also protect against off-target delivery. We know if you get more drug into a tumor, we know that can improve overall survival.

We know if we can protect off-target delivery, we reduce complications substantially, and that actually saves money and patients have better outcomes. This is a picture of our technology. Right on the end is where all the magic occurs. It's this smart valve on the end that looks like a little umbrella. What it does is it works physiologically with the heart during diastole and systole. Think of this almost like a tiny little auxiliary pump placed in the vessel that feeds the tumor. Inside a tumor, this is something we've just starting to recognize that the pressure inside the tumor is often higher than what the heart can pump at. If you dropped a pressure gauge, which we have, into solid tumors in the liver, in the pancreas, and in other cancers, the pressure can be anywhere from 110.

In pancreatic cancers, it can be as high as 200 millimeters of mercury. All of you guys are healthy adults. Your mean blood pressure is probably between 70 and 90, so that's 80 millimeters of pressure in your heart that your heart can pump at. In the tumor, if it's higher than that, none of the drug gets in. What our therapy does, we're primarily focused on liver embolizations right now, but this technology can improve therapy delivered to a wide range of different applications. Essentially, we're innovating a decade-old catheter technology, which is a tube with two holes. You can't influence where that goes or how exactly it can get into the tumor or overcome pressure. We have a specialized G-code that's written specifically for us across all sites of care.

We just received a new G-code, and then we're a very high-growth company focused on upgrading that technology across a wide range of different applications.

The TriNav ADVANCE. Yeah, I don't know if we have a slide here.

The TriNav ADVANCE is our new product. I can show you a picture of our whole portfolio. This is quite innovative because often if a physician, an interventional radiologist, wants to get to a particular tumor and the vessels are very tiny and very torturous, our valve wouldn't fit. What we did is design a new technology where they can put their standard microcatheter through it and still get the effect of enhanced delivery and protection of off-target delivery. We're waiting any day now to get FDA clearance. Once we have that configuration, we have 5 different vessel configurations that essentially we have the whole toolset for an interventional radiologist to access any type of vascular anatomy that they need.

Yeah. As a reminder for everyone, we took on a pretty substantial commercial expansion in the first half of the year. Our expanded commercial organization was largely in place in April, and that included essentially recruiting, training, and onboarding. They're about halfway through kind of that 6 to 9-month ramp to become fully productive. That ramp is really kind of what's driving our confidence. To answer your question with regards to what's giving us confidence is we have a very sophisticated model over the last 4 years that we've been looking at, and historically what we look at is our things in terms of physician engagements, how many engagements does it take to get a TriNav used? How do we get those TriNavs through VAC approvals? Most importantly, when do we see physicians start using in routine practice?

For us, we're looking at all those metrics. It is a little early for us to start reporting those externally, but we are seeing a very positive trend, not only in our legacy reps with their continued growth, but also those newer reps ramping to where we think they should be, and they are right on track.